Tolero Pharmaceuticals to deliver keynote presentations at the 9th International Conference on Leukemia and Hematologic Oncology
SALT LAKE CITY, Oct. 5, 2017 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematological diseases, today announced that Chief Executive Officer, David J. Bearss, Ph.D., and Vice President of Discovery and Development, Steven L. Warner, Ph.D., will each deliver a keynote presentation at the 9th International Conference on Leukemia and Hematologic Oncology. The conference is being held on October 5-6, 2017 in London, UK., and is a leading forum that brings together world leaders to discuss the latest innovations in leukemia and hematologic cancers.
Dr. Bearss will kick-off the conference at 09:45 BST on October 5 with a presentation titled, "Targeting MCL-1 Dependent Cancers by Cyclin Dependent Kinase 9 (CDK9) Inhibition." Following the conclusion of Dr. Bearss' presentation, Dr. Warner will present "Targeting Novel Kinases in Hematologic Malignancies."
"Recently, there have been many advances in hematologic cancers that have given us a better understanding of cancer biology and how to potentially target these malignancies. Despite available treatments, hematologic malignancies continue to result in high mortality," said David Bearss. "Our hope is that with the identification of new targets and therapeutic options, coupled with optimizing the use of available treatments, patients with hematologic cancers may achieve better outcomes."
Tolero is currently developing investigational agents alvocidib, TP-0903, and TP-3654.
Alvocidib is an investigational agent that is a small molecule inhibitor of cyclin-dependent kinase 9 (CDK9). Alvocidib is currently in development as part of combination therapy for frontline and relapsed/refractory MCL-1 dependent AML. CDK9 is a protein critical to the regulation of gene expression, including the MCL1 gene and other important genes involved in cancer. Given the potential role CDK9 de-regulation plays in expression of cancer-associated genes related to cell division and proliferation, CDK9 may be an attractive target for the treatment of various cancers.
TP-0903 is an investigational tyrosine kinase inhibitor that, in preclinical models, has been shown to inhibit AXL signaling and reverse the mesenchymal phenotype, both of which play a role in metastasis, tumor progression and resistance to cancer therapy. TP-0903 is currently being evaluated in a multicenter Phase I clinical trial in patients with solid tumors.
Tolero is also developing TP-3654, an investigational agent that is a second-generation small molecule inhibitor of Pim kinases. TP-3654 is in preclinical stage of research. Tolero plans to focus clinical development in cancer and blood diseases, such as myelofibrosis, a blood condition characterized by fibrotic scarring in the bone marrow compartment.
About Tolero Pharmaceuticals, Inc.
Tolero is a clinical-stage biopharmaceutical company researching and developing treatments to improve and extend the lives of patients with oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias, anemia, and solid tumors, as well as targets of drug resistance and transcriptional control. Tolero is based in the United States and is an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan.
Additional information about the company and its product pipeline can be found at www.toleropharma.com.
Tolero Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Tolero's business. Tolero undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Russo Partners, LLC